Prophylaxis of chronic kidney disease after liver transplantation - experience from west China

Table 2 Chronic kidney disease incidence between groups 3 mo and one year after liver transplantation

Groups	Cases (CKD incidence %)	P value
Three months after LT
CSA trough concentrations
> 150 ng/mL	20/60 (32.3)	0.036
≤ 150 ng/mL	15/83 (18.1)
TAC trough concentrations
> 8 ng/mL	32/136 (23.5)	0.001
≤ 8 ng/mL	32/293 (10.9)
One year after LT
CSA trough concentrations
> 120 ng/mL	19/41 (46.3)	< 0.001
≤ 120 ng/mL	12/79 (15.2)
TAC trough concentrations
> 6 ng/mL	36/147 (24.5)	< 0.001
≤ 6 ng/mL	17/183 (9.3)

Patients were divided by the calcineurin inhibitor types and trough concentrations 3 mo post transplantation. Groups with ideal trough concentrations [cyclosporine A (CSA) trough concentrations ≤ 150 ng/mL, tacrolimus (TAC) trough concentrations ≤ 8 ng/mL] had much lower chronic kidney disease (CKD) incidence. Patients followed-up over 1-year (n = 450) were divided by the calcineurin inhibitor types and trough concentrations at one year post transplantation. Groups with ideal trough concentrations (CSA trough concentrations ≤ 120 ng/mL, TAC trough concentrations ≤ 6 ng/mL) had much lower CKD incidence. LT: Liver transplantation.